There has been huge growth in the demand for transplantation procedures because of certain diseases, such as blood cancers and genetic blood disorders, where stem cell transplantation is needed. Over the years, the increased public awareness of organ transplantation and regulatory authorities' supporting regulation have increased the market forward. The market is expected to show major growth over the forecasted period with constantly growing transplant procedures globally.
Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/global-hla-typing-transplant-market
Data Bridge Market Research analyses that the Global Human Leukocyte Antigen (HLA) Typing for Transplant Market was valued at USD 778.19 million in 2021 and is expected to reach USD 1,483.61 million by 2029, registering a CAGR of 8.4% during the forecast period of 2022-2029. The increasing demand forhuman leukocyte antigen (HLA) typing for transplant will provide potential opportunities for the market growth in the forecast period.
The growing rate of organ transplantation is anticipated to drive the market's growth rate
The demand for organ transplantation has rapidly surged worldwide during the last few years because of the increased prevalence of vital organ failure, numerous diseases such as cancers and genetic diseases, the rising success and greater improvement in post-transplant outcome. Furthermore, innovations in transplant science are enabling a greater proportion of deceased donors from less traditional demographic and medical categories. The increasing demand for organ transplantation in developed and developing countries is expected to incraese the demand for HLA typing.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products and Services (Reagents and Consumables, Instruments, Software and Services), Technology (Molecular Assay Technologies, Non- Molecular Assay Technologies), Transplant Type (Solid Organ Transplant, Hematopoietic Stem Cell Transplant), Application (Diagnostic Applications, Research Application), End User (Independent Reference Laboratories, Hospitals and Transplant Centers, Research Laboratories and Academic Institutes)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Thermo Fisher Scientific (U.S), QIAGEN (Netherlands), Illumina (US), CareDx, (US), Immucor, (U.S), Bio-Rad Laboratories, Inc. (U.S), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (U.S), Luminex Corporation (U.S), Biofortuna (UK), Bruker (US), Abbott (US), Takara Bio Inc.,(Japan), Omixon Inc., (Hungary), Siemens (Germany), EKF Diagnostics (UK), BD (US), Fujirebio, (Japan), and TBG Diagnostics Limited (Australia)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global human leukocyte antigen (HLA) typing for transplant market is categorized into five notable segments based on products and services, technology, transplant type, application and end user.
- On the basis of products and services, the global human leukocyte antigen (HLA) typing for transplant market is segmented into instruments, reagents and consumables and software and services.
The instruments segment of products and services segment is anticipated to dominate the human leukocyte antigen (HLA) typing for transplant market
The instruments segment is expected to dominate the global human leukocyte antigen (HLA) typing for transplant market with 52.18% market share due to increasing demand for organ transplantation worldwide because of surging incidence of chronic diseases.
- On the basis of technology, the global human leukocyte antigen (HLA) typing for transplant market is segmented into molecular assay technologies, non-molecular assay technologies.
The molecular assay technologies segment of technology segment is anticipated to dominate the human leukocyte antigen (HLA) typing for transplant market
The molecular assay technologies segment is expected to dominate the global human leukocyte antigen (HLA) typing for transplant market with 81.59% market share because of increasing R & D activities for HLA typing which has ramped up the demand for HLA typing before organ transplant procedures.
On the basis of transplant type, the global human leukocyte antigen (HLA) typing for transplant market is segmented into solid organ transplant and hematopoietic stem cell transplant. The solid organ transplant segment is expected to dominate the global human leukocyte antigen (HLA) typing for transplant market with 64.93% market share due to growing advancement in technology because it is a life-saving or prolonging therapy for hundreds of thousands of patients globally.
- On the basis of application, the global human leukocyte antigen (HLA) typing for transplant market is segmented into diagnostic applications and research applications. The diagnostic applications segment is expected to dominate the global human leukocyte antigen (HLA) typing for transplant market with 59.84% market share as more market players are investing into bringing forth new innovative diagnostic applications for better patient treatment.
- On the basis of end user, the global human leukocyte antigen (HLA) typing for transplant market is segmented into hospitals and transplant centers, research laboratories and academic institutes and independent reference laboratories. The hospitals and transplant centers segment is expected to dominate the global human leukocyte antigen (HLA) typing for transplant market with 51.60% market share because of surging patient base for transplant procedure and rising public awareness.
Major Players
Data Bridge Market Research recognizes the following companies as the major human leukocyte antigen (HLA) typing for transplant market players in human leukocyte antigen (HLA) typing for transplant market are Thermo Fisher Scientific (U.S), QIAGEN (Netherlands), Illumina (US), CareDx, (US), Immucor, (U.S), Bio-Rad Laboratories, Inc. (U.S), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (U.S), Luminex Corporation (U.S), Biofortuna (UK), Bruker (US), Abbott (US), Takara Bio Inc.,(Japan), Omixon Inc., (Hungary), Siemens (Germany), EKF Diagnostics (UK), BD (US), Fujirebio, (Japan), and TBG Diagnostics Limited (Australia).
Market Development
- In 2020, Omixon launched OmniType, an 11-locus multiplex HLA genotyping assay and software product used on the Illumina sequencing platforms. The company's groundbreaking single-working-day workflow let the sample be processed from gDNA to a ready-to-sequence library within 6 hours. This launch is anticipated to boost the portfolio of the company.
- In 2020, Genome Diagnostics B.V. partnered with Berlin-based PIRCHE AG and the released of a new edition of their NGSengine® software. NGSengine, widely regarded as the ultimate Human Leukocyte Antigen (HLA) typing programme for several NGS systems, can now export individual sample HLA typing data to the PIRCHE matching services website.
Regional Analysis
Geographically, the countries covered in the human leukocyte antigen (HLA) typing for transplant market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in human leukocyte antigen (HLA) typing for transplant market during the forecast period 2022 to 2029
North America dominates the human leukocyte antigen (HLA) typing for transplant market due to the technological advancements in transplant diagnostics. This region will continue to dominate the market during the forecast period because of the growing healthcare expenditure..
Asia-Pacific is estimated to be the fastest-growing region in human leukocyte antigen (HLA) typing for transplant market the forecast period 2022 to 2029
Asia-Pacific is expected to grow from 2022 to 2029 due to the increasing awareness about donations and supportive regulations by the government in this region. In addition to this, the increasing presence of major market players and growing disposable income are anticipated to boost the market's growth rate in this region.
For more detailed information about Global Human Leukocyte Antigen (HLA) Typing for Transplant market report, click here – https://www.databridgemarketresearch.com/zh/reports/global-hla-typing-transplant-market
